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Table 1 Immunological and clinical parameters
Parameters Pretransplant
Post-
transplant
Reference 
range
Laboratory
  Haemoglobin (g/dL) 9.8 12.4 13.5–17.5
  Leucocytes (109/L) 1.88 3.47 150–450
  Lymphocytes (109/L) 0.17 1.31 1.2–5.2 
  Neutrophils (109/L) 1.52* 1.79 1.8–8.0
  Monocytes (109/L) 0.19 0.37 0.2–0.8
  Platelets (109/L) 29 183 150–400
  CD3+ (cells/µL) 800 1914 800–3500
  CD8+ (cells/µL) 554 936 200–1200
  CD4+ (cells/µL) 238 920 400–1200
  CD56+ (cells/µL) 35 99 70–1200
  CD19+ (cells/µL) 138 99 200–600 
  Activated T cells
  (HLA-DR+ %)
55 25 N/A
  CD4+ naive (%) Not detected 244 N/A
  CD27– IgD+ (naive) (%) 87 93 75.2–86.7
  CD27+ IgD+ (memory) (%) 9 4 4.6–10.2
  CD27+ IgD–
  (class-switched) (%)
2 3 3.3–9.6
  IgM (g/L) 0.55 0.25 0.50–1.90
  IgG (g/L) 6.4 8.2 5.4–16.1
  IgA (g/L) 0.92 0.33 0.80–2.80
  Tetanus (IU/mL) 0.93 ND 0.1–10 
  Haemophilus influenzae b (mg/
mL)
1.8 ND 1.0–20.0
  Pneumococcal (mg/mL) 10 ND 20–200
  Anti-GAD antibody (IU/mL) >2000 >2000 0–9.9
  Islet cell antibody Detected Detected N/A
  pANCA Detected Detected N/A
Clinical
  FEV1 (% predicted) 38 84 95–100
*Peripheral neutrophils were supported pretransplant by recombinant granulocyte 
colony stimulating factor. Post-transplant parameters were obtained at 18 
months (FBC and T-cell indices, lung function) or 21 months post-HSCT (B cell and 
antibody indices). Post-HSCT antibody indices were measured during concomitant 
subcutaneous immunoglobulin supplementation. No other autoantibodies were 
detected pre-HSCT or post-HSCT.
FBC, full blood count; FEV1, forced expiratory volume in 1 s; GAD, glutamic acid 
decarboxylase; HLA-DR, human leucocyte antigen–antigen D related; HSCT, 
haematopoietic stem cell transplantation; ND, not done; pANCA, perinuclear anti 
neutrophil cytoplasmic antibody. 
Early-onset autoimmune disease due to a 
heterozygous loss-of-function mutation in 
TNFAIP3 (A20)
Rare Mendelian disorders increasingly contribute to our under-
standing of the genetic architecture of autoimmune disease and 
the key molecular pathways governing its pathogenesis. Early-
onset autoimmune disease can arise through activating muta-
tions in inflammatory signalling pathways or loss-of-function 
mutations in immunoregulatory proteins.
We investigated the molecular basis of complex autoimmu-
nity—characterised by the onset of insulin-dependent diabetes, 
cytopaenias, hepatitis, enteropathy and interstitial lung disease 
at age 10—in a 14-year-old boy of healthy non-consanguin-
eous British parents. Immunological analysis revealed lympho-
paenia with no naive T cells and a high proportion of activated 
T cells (table 1). Pathogenic variants in STAT3 and FOXP3 were 
excluded. The clinical course was refractory to intensive immu-
nosuppression with prednisolone, sirolimus, tacrolimus, inflix-
imab or rituximab, necessitating haematopoietic stem cell trans-
plantation. Twenty-one months post-transplant, he is thriving off 
all immunosuppressive medication with complete remission of 
autoimmune disease (except diabetes).
Ethical approval was granted (ref: 10/H0906/22) and written 
informed consent provided prior to study commencement. By 
whole exome sequencing of peripheral blood genomic DNA 
(Illumina MiSeq) and downstream bioinformatic filtering (Inge-
nuity Variant Analysis), we identified a single biologically plau-
sible variant—a novel de novo heterozygous 2 bp deletion in 
tumour necrosis factor-alpha-induced protein 3 (TNFAIP3, 
figure 1A). TNFAIP3 encodes the ubiquitin-editing enzyme 
A20, a negative regulator of the nuclear factor-κB (NF-κB) 
pathway.1 A20 removes K63-linked ubiquitin chains from key 
adaptor proteins, replacing them with K48-linked polyubiquitin 
chains, to trigger proteasomal degradation and termination of 
the NF-κB activation cascade.2 Polymorphisms in TNFAIP3 have 
been linked to the development of several autoimmune diseases 
in genome-wide association studies.3–7 A conditional knockout 
of A20 in immune cells leads to the development of autoim-
munity in the mouse.8 However, autoimmune phenomena were 
not prominent in a recently described cohort of patients with 
germline A20 haploinsufficiency, who instead presented with an 
autoinflammatory phenotype resembling Behçet’s disease.9
The c.1466_1467delTG variant—which we confirmed by 
capillary sequencing10 (figure 1B)—introduces a frameshift 
substitution of alanine for valine at position 489, generating 
a downstream premature stop codon (p.V489Afs*7) in the 
zinc finger (ZnF)2 domain of A20. This variant is absent from 
public databases (ExAc/dbSNP) and distinct from disease-associ-
ated mutations affecting the ovarian tumour or ZnF4 domains 
of A209 (figure 1C). Immunoblotting10 of patient and control 
dermal fibroblast lysates with an N-terminal antibody confirmed 
the reduced basal and TNF-α-induced expression of A20 
(figure 1D).
To address the consequence of this reduced A20 expression, 
we performed functional experiments in patient and control 
dermal fibroblasts. Initially, we stimulated these cells with TNF-α 
(10 ng/mL) and analysed downstream signalling events by immu-
noblot (figure 1E). We observed exaggerated and prolonged 
phosphorylation of components of the NF-κB pathway, which 
would be expected to enhance NF-κB-dependent transcriptional 
effects. In keeping with this prediction, RNA sequencing (Illu-
mina NextSeq-500) revealed a significant global increase in 
both the range and magnitude of TNF-α-stimulated differential 
gene expression (fold-change ≥2; false discovery rate-adjusted 
p≤0.01, figure 1F). We also confirmed enhanced expression of 
the key NF-κB target gene interleukin 6 (IL-6) at the protein 
level by ELISA (p=0.0015, figure 1G). In these respects, the 
molecular consequences of the p.V489Afs*7 variant were indis-
tinguishable from reported pathogenic A20 mutations,9 although 
owing to the lack of leucocyte material, we were not able to 
extend our analysis to inflammasome activation.
Here we provide novel validation of considerable existing 
evidence that implicates TNFAIP3 in autoimmune pathogenesis. 
This case expands the clinical spectrum of A20 haploinsuffi-
ciency.9 As A20 regulates multiple innate and adaptive signalling 
pathways,1 it is logical that patients with inactivating mutations 
in A20 might manifest pathological features of autoimmunity 
Letter
 ARD Online First, published on June 28, 2017 as 10.1136/annrheumdis-2016-210944
Copyright Article author (or their employer) 2017. Produced by BMJ Publishing Group Ltd (& EULAR) under licence. 
group.bmj.com on November 8, 2017 - Published by http://ard.bmj.com/Downloaded from 
2 Ann Rheum Dis Month 2017 Vol 0 No 0
Figure 1 TNFAIP3 variant identification and functional validation. (A) The family pedigree is shown (triangles are used to preserve the anonymity 
of healthy unaffected siblings). The first-born infant died as a result of prematurity. Whole exome sequencing data were filtered (Ingenuity Variant 
Analysis) by confidence (call quality ≥20; read depth ≥10; allele fraction ≥45%); frequency (ExAc allele frequency ≤0.01%); deleteriousness 
(nonsense/deleterious missense (SIFT/PolyPhen), splice-site disruption); genetic segregation (ie, present in patient and absent from 47 unrelated 
disease controls) and biological function (linked to phenotype), identifying a single heterozygous frameshift variant in TNFAIP3 (c.1466_1467TGdel). 
(B) Variant confirmation by Sanger sequencing. (C) The c.1466_1467TGdel variant resulted in a frameshift and premature stop codon (V489Afs*7) 
in the second ZnF domain and is distinct from previously described mutations in the OTU and ZnF4 domains (blue). (D) V489Afs*7 reduced basal 
and TNF-induced A20 protein in patient (P) versus control (C1, C2) fibroblasts (immunoblot representative of n=4 independent experiments with 
n=4 controls). (E) Signalling responses downstream of TNF-α stimulation in patient fibroblasts were exaggerated and prolonged compared with 
control (immunoblot representative of n=4 independent experiments with n=4 controls). (F) RNA-seq analysis of transcriptional response to 
6-hour TNF-α stimulation in patient and control fibroblasts (stimulations performed in triplicate in a single experiment). Top panel: displayed in 
red are significant (FDR-corrected p≤0.01) DE transcripts regulated ≥4 fold (≥2log2-fold); middle panel: Venn diagram displaying all overlapping 
DE transcripts ≥2 fold (≥log2-fold); Bottom panel: top 20 significant DE transcripts in patient (red bars) versus control (black bars), demonstrating 
many major NF-κB target genes. (G) Levels of IL-6 quantified by ELISA in supernatants from patient and control fibroblasts stimulated with 
TNF-α for 24 hours (mean±SD of average values from two independent experiments in patient and n=4 controls compared by one-sample t-test; 
**p=0.0015). DE, differentially expressed;  FDR,  false discovery rate; IL-6, interleukin 6; NF-κB, nuclear factor-κB; OTU, ovarian tumour; PolyPhen, 
polymorphism phenotyping; SIFT, Sorting Intolerant from Tolerant; TNF-α, tumour necrosis factor-alpha; TNFAIP3, tumour necrosis factor-alpha-
induced protein 3; ZnF, zinc finger.
Letter
and/or autoinflammation. Finally, we report that correction of 
the molecular defect within the haematopoietic cell compart-
ment could represent a viable treatment option for severe clin-
ical manifestations.
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